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Summary
 
OBJECTIVE
 
 
 
To analyse the association of the 
 
UCP2
 
gene, alone or in combination with the PPARγ
 
2 gene,
with obesity.
 
DESIGN
 
 
 
Cross-sectional, case–control study.
 
STUDY
 
 
 
POPULATION
 
 
 
From a working population of
4500 Italian Caucasian employees of the Italian tele-
phone company participating in a firm-sponsored
health screening programme, we selected all those with
obesity [
 
n
 
 = 122; body mass index (BMI) ≥
 
 30 kg/m
 
2
 
].
For each case, three nonobese age- and sex-matched
individuals were selected as controls from the same
population (
 
n
 
 = 374). Included in the study were also
76 severely obese (BMI ≥
 
 40 kg/m
 
2
 
) patients consecu-
tively admitted to the obesity clinic of the department.
Diabetic individuals were excluded.
 
MEASUREMENTS
 
 
 
The −
 
866G/A UCP2 and the Pro12Ala
PPARγ
 
2 polymorphisms were determined on genomic
DNA of the studied individuals. Several metabolic and
anthropometric measures were also obtained, like
plasma glucose, insulin, triglycerides, total choles-
terol, high-density lipoprotein (HDL) cholesterol and
BMI.
 
RESULTS
 
 
 
BMI, plasma glucose, insulin, triglycerides,
total and HDL cholesterol were not significantly differ-
ent in carriers and noncarriers of the −
 
866G/A variant.
No significant association was observed between the
−
 
866G/A UCP2 gene polymorphism and moderate or
severe obesity. This was also observed when the UCP2
polymorphism was analysed in combination with the
PPARγ
 
2 polymorphisms.
 
CONCLUSIONS
 
 
 
The −
 
866G/A variants of the UCP2 gene
are not associated with either obesity or other features
of the metabolic syndrome in the studied groups of the
Italian population. This negative finding is not modified
after a combined analysis of the UCP2 polymorphism
and the Pro12Ala polymorphism of PPARγ
 
2.
 
The genetic control of metabolism is still an open field of
research both from a physiological and a pathological perspec-
tive. Genetic factors are involved in the multifactorial origin of
the most important metabolic diseases. Recent knowledge about
the uncoupling proteins (UCPs) has indicated possible novel
molecular links among energy metabolism, obesity and diabetes
(Zhang 
 
et al
 
., 2001). UCPs are inner mitochondrial membrane
transporters and are considered pivotal regulators of energy
homeostasis; they can uncouple mitochondrial oxidative
phosphorylation by dissipating the respiration-derived proton
gradient across the inner mitochondrial membrane, therefore
transforming energy into heat (Boss 
 
et al
 
., 2000; Ricquier &
Bouillaud, 2000). Differences in this mechanism could be one
of the molecular bases of the genetic predisposition to obesity
and type-2 diabetes in humans (Dalgaard & Pedersen, 2001;
Argilés 
 
et al
 
., 2002). Although a physiological, cold-induced,
thermogenic role has been established for UCP1 in brown adi-
pose tissue (BAT), it is still unclear what are the functions of
UCP2, -3, -4 and -5, the other isoforms so far identified. While
UCP3 is preferentially expressed in skeletal muscle and UCP4
and -5 are specifically found in brain, the ubiquitous distribution
of UCP2, including pancreatic beta-cells, is particularly well-
suited for a dual function in the control of energy and glucose
metabolism. Very recently, a role for UCPs has been proposed
in a feedback control of reactive oxygen species inside mito-
chondria (Echtay 
 
et al
 
., 2002). Several papers have been pub-
lished about the association of natural variants of UCPs and body
mass index (BMI; reviewed in Schonfeld-Warden & Warden,
2001). Although not all studies draw concordant conclusions,
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UCP2 appears the strongest contributor to BMI, as compared to
UCP1 and UCP3. A recent paper about this issue is particularly
convincing because reported an association among a polymor-
phism in the 
 
UCP2
 
 promoter (
 
−
 
866 G/A), increased level of
adipose tissue 
 
UCP2
 
 mRNA 
 
in vivo
 
, an higher transactivating
capacity in 
 
in vitro
 
 assays and a decreased risk of obesity in
humans (Esterbauer 
 
et al
 
., 2001). Although the evidence
provided in this paper is very strong due to the convergence of
experimental and epidemiological evidence, several potential
limitations apply to association studies. In fact, environmental
and genetic differences between populations may account for dif-
ferent results of different studies. Therefore, it may be helpful to
replicate a similar study in a different setting. It is also plausible
that gene interactions are potentially important in the aetiology
of complex diseases like obesity, and it has been suggested that
multiple gene interactions may lead to a synergistic effect in the
development of obesity (Hsueh 
 
et al
 
., 2001). This is particularly
intriguing when two or more genes are candidate genes, whose
expression and function can be reciprocally influenced as it has
been suggested for UCPs and peroxisome proliferator-activated
receptors (PPARs). PPARs are ligand-activated nuclear receptors
that regulate transcription of genes involved in lipid and glucose
metabolism, adipocyte differentiation, inflammation and, pro-
bably, cancerogenesis (Desvergne & Wahli, 1999). The PPAR-
 
γ
 
isoform, in particular, plays an important role in adipose tissue
and several reports have evaluated the relationship of genetic
polymorphisms of PPAR-
 
γ
 
 and BMI or obesity, but conflicting
evidence was obtained (Beamer 
 
et al
 
., 1998; Deeb 
 
et al
 
., 1998;
Mori 
 
et al
 
., 1998; Ek 
 
et al
 
., 1999; Mancini 
 
et al
 
., 1999; Vaccaro
 
et al
 
., 2002). Interestingly, it has been reported that PPARs can
affect UCP2 expression (Aubert 
 
et al
 
., 1997; Rieusset 
 
et al
 
.,
1999; Viguerie-Bascands 
 
et al
 
., 1999; Chevillotte 
 
et al
 
., 2001).
Therefore, we resolved to study the relation of the 
 
−
 
866G/A poly-
morphism in the 
 
UCP2
 
 gene with obesity and several metabolic
parameters and subsequently to repeat the analysis combining the
UCP2 polymorphism with the Pro12Ala variant of 
 
PPAR
 
γ
 
, in
unrelated Italian Caucasian people. Furthermore, we tested the
relationship between UCP2 with several metabolic parameters,
like plasma lipids, glucose and insulin, which could be influenced
by this gene.
 
Materials and methods
 
Study population
 
Of 4500 employees of the Italian Telephone Company in the age
range 35–65 years, participating in a firm-sponsored health
screening, all those with obesity (BMI 
 
≥
 
 30 kg/m
 
2
 
, 91 men, 31
women) were selected to participate in the study; this group is
referred to as ‘group 1’. For each case, three nonobese controls
(BMI < 30 kg/m
 
2
 
, 258 men, 116 women), matched on age and
sex, were also selected from the same reference population. Also
included in the study were 76 young adults with severe, uncom-
plicated obesity (BMI 
 
≥
 
 40 kg/m
 
2
 
, i.e. WHO class 3, 41 men, 35
women; WHO, 1997) manifesting early in life (i.e. before
40 years of age) who were consecutively seen at the obesity clinic
of the department over a three-month period. This group is
referred to as ‘group 2’. Specific exclusion criteria were diabetes
(i.e. fasting plasma glucose 
 
≥
 
 7 mmol/ l, or under medication for
diabetes) or use of hypolipidaemic drugs. All participants were
Caucasians of Italian origin residents in the Campania region in
Southern Italy. None were taking drugs for weight control or
affecting glucose or lipid metabolism. Informed consent was
obtained from all participants; the study protocol was approved
by the local ethics committee.
 
Measurements
 
Height and weight were measured in light underclothing. BMI
(kg/m
 
2
 
) was calculated.
Blood pressure was measured in supine position after a 5-min
rest. The average of three readings taken 2 min apart was used
in the analysis.
Blood samples were collected after an overnight fasting.
Plasma glucose, triglycerides, total cholesterol and high-density
lipoprotein (HDL) cholesterol were measured with an Ektakem
DT-60 (Eastman Kodak, Rochester, NY, USA) using already
validated dry chemistry methodologies (El-Deriny 
 
et al
 
., 1986;
Marotta 
 
et al
 
., 1994). Accuracy and reproducibility were moni-
tored by daily determination of all the above parameters on each
of two reference sera (normal and high concentration). The accu-
racy was 1·2% for HDL cholesterol, 2·1% for total cholesterol,
3·6% for triglycerides and 3·0% for glucose. Reproducibility, as
assessed by the calculation of the between-day coefficient of var-
iation was 6·3% for HDL cholesterol, 4·0% for total cholesterol,
5·9% for triglyceride and 3·6% for plasma glucose. Plasma insu-
lin was measured by radioimmunoassay on frozen samples (Roth
 
et al
 
., 1973); the detection limit was less than 7 pmol/ l. The intra-
assay and interassay coefficients of variation were 3·0% and
5·8%, respectively, at the level of 174 pmol/ l. Insulin resistance
was estimated with the homeostatic model assessment (HOMA),
a technique validated against clamp studies, and suited for pop-
ulation studies (Mattheus 
 
et al
 
., 1985; Bonora 
 
et al
 
., 2000).
 
DNA assays
 
Genomic DNA was purified from peripheral blood leucocytes
(Miller 
 
et al
 
., 1988). Both UCP2 and PPAR
 
γ
 
2 variants were
determined by restriction enzyme digestion of DNA fragments
generated by polymerase chain reaction. Detailed experimental
procedures have been already reported (Mancini 
 
et al
 
., 1999;
Esterbauer 
 
et al
 
., 2001). For 5% of the samples, genetic analysis
 UCP2 polymorphism and obesity
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was performed on duplicates in a blinded fashion and a 100%
concordance of results was obtained.
 
Statistical analysis
 
Data are given as mean and standard deviation or percentages.
Log-transformed values were used in the analysis of very skewed
variables like plasma insulin and triglyceride concentrations; the
original values are given in Tables 1 and 2. The statistical analysis
was performed with the SPSS package for Windows. Unpaired
Student 
 
t
 
-test and analysis of variance were used to compare
means. Proportions were compared by 
 
χ
 
2
 
 analysis.
 
Results
 
Pertinent clinical data of the three study groups are given in
Table 1. By study design, obese people in group 2 were substan-
tially and significantly younger and heavier as compared to obese
people in group 1 (age: 31 
 
±
 
 7 
 
vs.
 
 46 
 
±
 
 8; BMI: 50·2 
 
±
 
 9·3 
 
vs.
 
36·2 
 
±
 
 4·8). There were some expected significant differences
between obese individuals and nonobese controls, such as higher
fasting glucose and triglycerides in group 1, and higher insulin,
HOMA and lower HDL cholesterol in both groups 1 and 2 as
compared to the control group.
In Table 2, frequencies of the 
 
−
 
866G/A polymorphism of
UCP2 are given for nonobese controls and the two different
groups of obese people. The prevalence of 866G/A genotypes of
 
UCP2
 
 was not significantly different in obese (both group 1 and
group 2) and nonobese participants (
 
χ
 
2
 
 = 7·3; 
 
P
 
 = 0·2).
To explore whether the 
 
UCP2–
 
866G/A polymorphism is
related to BMI and other variables related to insulin resistance,
we compared the mean values of BMI, plasma glucose, insulin
and triglycerides in the two groups of obese and nonobese
controls across UCP2 genotypes (Table 2). No significant
differences were found among the three different genotypes
either in obese or in nonobese participants; in particular, no
differences were observed between carriers and noncarriers of
the 866G/A variant in regard to BMI or metabolic variables
associated with insulin resistance.
Furthermore, the 
 
−
 
866G/A polymorphism of the 
 
UCP2
 
 gene
was analysed in combination with the Pro12Ala variant of
PPAR
 
γ
 
2 (data not shown). No significant differences were
detected in the distribution of the combined genotypes between
nonobese controls and both groups of obese participants. In par-
ticular, the genotype combination hypothetically more protective
against obesity (Pro/Pro with A/A + G/A) was not more frequent
in nonobese (5·6%) 
 
vs.
 
 obese individuals (9·8 and 9·2% in the
two obese groups). Similarly, the genotype combination suppos-
edly more predisposing to obesity (Pro/Ala + Ala/Ala with G/G)
was not significantly more frequent in obese (8·2 and 7·9% in
the two obese groups) 
 
vs.
 
 nonobese individuals (7·8%).
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Discussion
The worldwide spreading of overweight and obesity in the gen-
eral population is a threat for human health due to the promoting
action on chronic-degenerative diseases. Although environmen-
tal factors are well known and have a profound effect on body
weight, unravelling the genetic component predisposing to obes-
ity is a very active field of research and the list of candidate genes
for this condition is constantly growing (Rankinen et al., 2002).
UCPs have attracted a lot of attention because they can mod-
ulate energy conservation and dissipation, thus providing a
potential contribution to the development of metabolic disorders
like obesity and diabetes. However, the pathophysiological role
of UCPs, with the exception of the thermogenic function of
UCP1, has not been clearly established. Two seminal papers
report concordant data about a negative association between
UCP2 levels in pancreatic beta-cells and insulin secretion (Chan
et al., 2001; Zhang et al., 2001). Also, the physiological role of
UCP3 is still elusive. Mice overexpressing UCP3 are hyper-
phagic and lean, and de novo expression of UCP3, after fenofi-
brate treatment, has been associated to reduced weight gain and
adiposity in diet-induced obese rats (Mancini et al., 2001; Lanni
et al., 2002). However, UCP3-knockout mice are not obese
(Clapham et al., 2000; Vidal-Puig et al., 2000).
In humans, several genetic studies have looked at the associ-
ation of naturally occurring variants of UCP genes and metabolic
parameters and syndromes (reviewed in Schonfeld-Warden &
Warden, 2001). Although not all studies are concordant, espe-
cially UCP2 appears to be related with BMI. Recently, it has been
demonstrated that the −866G/A common polymorphism in the
promoter of UCP2 is associated to an increased in vivo level of
adipose tissue mRNA, increased transcription rate in vitro and a
reduced risk of obesity in humans (Esterbauer et al., 2001). In
the present study we have investigated the relationship of this pol-
ymorphism of the UCP2 promoter with obesity in a sample of
Italian Caucasians, all coming from the same geographical area
around Naples in Southern Italy. In particular, we studied two
different phenotypes of obesity: a population-based group of
middle-aged, moderately obese individuals (average BMI of
36·2 kg/m2) and a clinic-based sample of young adults with
uncomplicated, severe obesity (average BMI of 50·2 kg/m2),
manifesting early in life. In this latter, more homogeneous group
a stronger contribution of the genetic background to the meta-
bolic disorder should be expected as higher heritability for severe
obesity with early onset as compared to obesity acquired later in
life is described (Rosenbaum et al., 1997). This notwithstanding,
the distribution of UCP2 genotype was not significantly different
between nonobese and both groups of obese individuals.
Table 2 BMI and measured plasma levels of metabolic variables by UCP2 polymorphism in obese and nonobese people
 
UCP2 Polymorphism A/A A/G G/G P between groups
Controls nonobese (n = 374) (n = 26) 7·0% (n = 165) 44·1% (n = 183) 48·9%
BMI (kg/m2) 24·2 ± 2·2 24·1 ± 2·5 24·2 ± 2·0 NS
Glucose (mmol/ l) 5·75 ± 1·75 6·14 ± 1·94 6·37 ± 2·63 NS
Triglycerides (mmol/ l) 1·29 ± 0·61 1·57 ± 0·89 1·55 ± 0·93 NS
Cholesterol (mmol/ l) 5·22 ± 0·70 5·30 ± 1·09 5·25 ± 1·01 NS
HDL cholesterol (mmol/ l) 1·22 ± 0·35 1·25 ± 0·38 1·29 ± 0·38 NS
HOMA 2·0 ± 1·4 2·2 ± 1·6 2·2 ± 1·5 NS
Group 1
Moderately obese (n = 122) (n = 13) 10·7% (n = 43) 35·2% (n = 66) 54·1%
BMI (kg/m2) 34·6 ± 3·6 37·2 ± 3·9 35·9 ± 4·4 NS
Glucose (mmol/ l) 5·77 ± 0·56 5·44 ± 0·72 5·55 ± 0·56 NS
Triglycerides (mmol/ l) 2·00 ± 0·86 1·77 ± 0·71 1·80 ± 0·83 NS
Cholesterol (mmol/ l) 5·92 ± 1·14 5·66 ± 1·14 5·51 ± 0·98 NS
HDL cholesterol (mmol/ l) 1·08 ± 0·15 1·23 ± 0·34 1·20 ± 0·36 NS
HOMA 2·5 ± 0·9 3·4 ± 2·7 2·9 ± 1·9 NS
Group 2
Severely obese (n = 76) (n = 7) 9·2% (n = 39) 51·3% (n = 30) 39·5%
BMI (kg/m2) 48·7 ± 8·5 50·1 ± 10·0 50·6 ± 8.7 NS
Glucose (mmol/ l) 5·66 ± 0·50 5·22 ± 0·56 5·27 ± 0·50 NS
Triglycerides (mmol/ l) 2·14 ± 0·92 1·85 ± 0·75 1·94 ± 0·85 NS
Cholesterol (mmol/ l) 4·62 ± 1·10 4·97 ± 0·82 4·58 ± 1·14 NS
HDL cholesterol (mmol/ l) 1·13 ± 0·38 1·16 ± 0·31 1·07 ± 0·25 NS
HOMA 5·8 ± 2·2 5·8 ± 3·0 6·5 ± 3·2 NS
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The possibility of a type 2 error should be taken into account.
With the sample size studied we have a 80% power of detecting
a relative risk of about 0·6 or less for the presence of the mutated
allele (A/A + A/G) in obese vs. nonobese controls with a signif-
icance of 0·05 (i.e. a 40% reduction in the risk of obesity asso-
ciated with the A variant). A smaller contribution may be missed,
and would be in line with the concept that obesity is multi-
factorial with a polygenic background and strong environmental
component which may mask the small effect of many genes. We
believe that the presence of the group of extremely obese young
people, i.e. with an average BMI of 50 kg/m2 and a mean age
of 31 years, gives additional strength to the present data because
it is a particularly well-suited sample to reveal a genetic basis
for obesity.
Our data are at variance with those of Esterbauer et al. (2001);
possible explanations include difference in the geographical
origin of the study populations, which may result in different genetic
and environmental background: other close loci with potential
influence on the same phenotype, like UCP3, could be different;
moreover, it is well known that nutritional habits vary in Europe
from north to south. It is also known that PPARs are activated
by nutrients like long-chain fatty acids. Finally, gender distribu-
tion is quite different between the two studies: male/female ratio
is 2·1 in our study and 0·3 in the population studied by Esterbauer
et al. (2001), and the same authors report that allele frequencies
for UCP2–866A/G polymorphism are quite different between
males and females.
We also explored the hypothesis of gene–gene interaction
between the variants of the PPARγ and UCP2 genes by analysing
the combined effect of the two polymorphisms, Pro12Ala of
PPARγ2 and −866G/A of UCP2. This hypothesis was particu-
larly stimulating because PPARγ2 is a very strong candidate for
interacting with UCP2 in the pathogenesis of obesity. In partic-
ular, the Pro12Ala substitution occurs within the ligand-
independent activation domain and could have functional relevance.
Moreover, PPARγ2 can affect the level of UCP2 by direct induc-
tion of gene expression or by modulating the levels of fatty acids,
which in turn influence the levels of UCP2 gene transcription.
However, we did not observe a reduction of the risk of obesity
associated with any combination of the −866G/A polymorphism
of the UCP2 promoter and the Pro12Ala polymorphism of
PPARγ2. Although with subgroup analysis the power of the study
is further reduced, this might be partly compensated for by the
hypothetically stronger association of the combined genetic
polymorphisms with the phenotype analysed.
In conclusion, this study does not confirm an association of
the risk of obesity with the −866G/A UCP2 polymorphism in
different groups of the Italian Caucasian population. In addition,
no relation was found between this polymorphism and BMI or
markers of insulin resistance. Moreover, no interaction was
observed between the −866 UCP2 polymorphism and the
Pro12Ala variant of PPARγ2 in the association with obesity.
Although these are negative data, they still endorse the need for
more efforts to disclose the complex genetic bases of such an
important disease like obesity.
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